Here we report two cases of isolated diffuse mesangial sclerosis (IDMS) with early onset end-stage renal failure. These female patients did not show abnormalities of the gonads or external genitalia. Direct sequencing of WT1 PCR products from genomic DNA identified WT1 mutations in exons 8 (366 Arg>His) and 9 (396 Asp>Tyr). These mutations have been reported previously in association with Denys-Drash syndrome (DDS) with early onset renal failure. Therefore we suggest that, at least in part, IDMS is a variant of DDS and that investigations for the WT1 mutations should be performed in IDMS patients. In cases with identified WT1 mutations, the same attention to tumor development should be required as in DDS patients, and karyotyping and serial abdominal ultrasonograms to evaluate the gonads and kidney are warranted.
Base Sequence ; DNA/chemistry/genetics ; DNA Mutational Analysis ; Fatal Outcome ; Female ; Glomerular Mesangium/*pathology ; Humans ; Infant ; Infant, Newborn ; *Mutation ; Nephrosclerosis/*genetics ; WT1 Proteins/*genetics

OBJECTIVEWilms' tumor (WT) is the most common malignant renal tumor in childhood. The WT1 gene located at 11p13 was identified in 1990 as a tumor suppressor gene important in the development in WT. The WT1 gene consists of 10 exons, with exons 1 to 6 encoding an N-terminal proline- and glutamine-rich transactivational domain, and exons 7 to 10 encoding a C-terminal zinc-finger domain involved in DNA binding. In China we know little about the frequency and genotype of WT1 mutations in Chinese WT patients. This study aimed to determine the frequency and genotype of WT1 mutations in children with nonsyndromic WT in China.

METHODSWe collected peripheral blood of WT patients treated in Beijing Children's Hospital. Genomic DNA of 54 WT patients was isolated from blood samples. All coding WT1 exons and their flanking intronic sequences were amplified by PCR method. The amplified PCR products from all individuals were then subjected to automatic DNA sequencing.

RESULTSFour different constitutional WT1 mutations were identified in four children. Three mutations are predicted to produce truncated protein. One mutation is missense. Of the four mutations, three had not been reported before. Patient 1 had a 1006 A > T transition in exon 7, which caused (336)Lys to become a stop codon (K336X). DNA sequence analyses in patient 2 indicated the point mutations in exon 9 which was a 1168 C > T substitution and caused (390)Arg to become a stop codon (R390X). It indicated a point mutations in exon 6 in patient 3 which was a 814 G > T substitution and resulted in (272)Glu to become a stop codon (E272X). In patient 4 there was a homozygous mutation in exon 10. The mutation was a 1228 A > G substitution and resulted in (410)Ser to become a Gly codon (S410G).

CONCLUSIONConstitutional WT1 mutations occur at a low frequency (7.4%) in Chinese patients with Wilms' Tumor. It is similar to the results of overseas study. Four WT1 gene mutations were confirmed, three were nonsense, one was missense.

Child ; Child, Preschool ; DNA Mutational Analysis ; Female ; Genes, Wilms Tumor ; Humans ; Infant ; Kidney Neoplasms ; genetics ; Male ; Mutation ; WT1 Proteins ; genetics ; Wilms Tumor ; genetics

This study was purposed to investigate the value of combination of pentamer and intracellular IFNgamma staining in the qualitative and quantitative detection of circulating antigen-specific T cells. WT1 expressions in 14 HLA-A*0201+ patients and their matched donors were detected by RT-PCR, and circulating WT1 specific T cells were assayed by HLA-A*0201/WT1 pentamer combined with intracellular IFNgamma+ staining. The results showed that the low level of WT1 expression was found only in 2 cases out of 14 donors, but different levels of WT1 expression could be observed in all leukemic patients. The WT1+CD8+ CTL and WT1+IFNgamma+ cells did not detected in all 14 donors, but WT1+CD8+ CTL cells in 2 patients and WT1+IFNgamma+ cells in 3 patients could be detected before transplantation respectively, there was no significant difference between them, while the WT1+CD8+ CTL cells and WT1+IFNgamma+ cells both could be detected in all 14 patients after transplantation, the positive detection rate after transplantation was obviously higher than that before transplantation. The WT1+CD8+ and WT1+ IFNgamma+ cells could be detected within 30 days after transplantation, but the positive detection rate of WT1+IFNgamma+ cells was higher than that of WT1+CD8+ CTL cells (p=0.014). The median peak value of WT1+CD8+ CTL cells was 0.18% in 14 patients, and the median peak value of WT1+IFNgamma+ cells was 0.83% in 14 patients, the later was significantly higher than former. The median peak time of WT1+CD8+ CTL cells was 75 days after transplantation, while the WT1+IFNgamma+ cells was 105 days after transplantation, there was no significant difference between them. It is concluded that pentamer and intracellular IFNgamma staining may effectively detect circulating WT1 specific T cells in leukemic patients, and the combination of these two methods profit to the exact qualitation and quantitation of circulating antigen-specific T cells.
Adolescent ; Adult ; Child ; Female ; Flow Cytometry ; HLA-A Antigens ; analysis ; HLA-A2 Antigen ; Humans ; Interferon-gamma ; analysis ; Leukemia ; blood ; genetics ; immunology ; Male ; Middle Aged ; Staining and Labeling ; T-Lymphocytes, Cytotoxic ; immunology ; metabolism ; WT1 Proteins ; genetics ; immunology ; metabolism ; Young Adult

OBJECTIVEAutosomal recessive steroid-resistant nephrotic syndrome (SRNS) is a subgroup of familial nephrotic syndrome. A causative gene has been identified, that is NPHS2, in chromosome 1q25-31, which encodes podocin. This study aimed to detect NPHS2 mutation in a Chinese family with SRNS.

METHODSRenal biopsy was performed on the proband and her sibling for routine histologic and immunohistochemical investigation and electron microscopic examination. The expressions of podocin, nephrin, alpha-actinin and WT1 in glomeruli of the proband were detected by indirect immunofluorescence. Peripheral blood samples were collected for genetic analysis from the proband and her parents, and 53 adults with normal urinalysis. Genomic DNA was isolated from peripheral blood leucocytes. Eight exons of NPHS2 were amplified by polymerase chain reaction. Mutational analysis was performed using denaturing high-performance liquid chromatography (DHPLC) and DNA fragments with aberrant elution profiles of both strands revealed by DHPLC were re-amplified and sequenced directly.

RESULTSThe histologic findings on kidney biopsies were focal segmental glomerulosclerosis. In controls, the distribution of staining with P35, rabbit against a human podocin recombinant protein (amino acids 135 - 383 = all the C-terminal part of the protein downstream the transmembrane domain), and P21, rabbit against a human podocin recombinant protein (amino acids 15 - 89 = all the N-terminal part of the protein upstream the transmembrane domain) showed a linear pattern along glomerular capillary walls on glomeruli, and the fluorescent intensity of the staining with P35 was intensely positive. The fluorescent intensity of the staining with P21 was positive. In the proband, the distribution of the staining with P35 showed uneven and nonlinear, and the fluorescent intensity of the staining with P35 was weakly positive. The staining with P21 was negative. The area, location, distribution and fluorescent intensity of the staining with nephrin, alpha-actinin and WT1 on glomeruli of the proband were the same as those in the controls. The DHPLC elution profiles of exon 4 of NPHS2 from the proband and her parent were aberrant. The chromatograms by sequencing detected in the exon 4 of NPHS2 showed a composite heterozygous mutation of both 467_468insT and 503G > A in the proband, a heterozygous mutation of 503G > A in her father, and a heterozygous mutation of 467_468insT in her mother, respectively.

CONCLUSIONThe study demonstrated for the first time a novel mutation, 503G > A, of NPHS2 in Chinese kindred with autosomal recessive SRNS. A significantly decreased or negative expression was also revealed in glomeruli of the proband stained with two kinds of anti-podocin antibodies.

Actinin ; analysis ; Adult ; Aged ; Base Sequence ; Child ; DNA Mutational Analysis ; Drug Resistance ; Female ; Fluorescent Antibody Technique, Direct ; Humans ; Infant ; Intracellular Signaling Peptides and Proteins ; Kidney ; immunology ; pathology ; Male ; Membrane Proteins ; analysis ; genetics ; Mutation ; genetics ; Nephrotic Syndrome ; genetics ; Pedigree ; Polymerase Chain Reaction ; Proteins ; analysis ; WT1 Proteins ; analysis

The genetic variant rs16754 of Wilms tumor gene 1 (WT1) has recently been described as an independent prognostic factor in AML patients. It is of great interest to test whether WT1 single nucleotide polymorphism can be used as a molecular marker in other types of cancer, to improve risk and treatment stratification. We performed sequencing analysis of exons 7 and 9 of WT1, which are known mutational hotspots, in a total of 73 patients with BCR-ABL1-negative myeloproliferative neoplasm (MPN) and 93 healthy controls. No previously reported WT1 mutations were identified in the present study. In Korean patients with BCR-ABL1-negative MPN, WT1 genetic variant rs16754 had no significant impact on clinical outcomes. We observed a significant difference in the allelic frequencies of WT1 rs16754 in Koreans between BCR-ABL1-negative MPN cases and healthy controls. Individuals carrying variant G alleles of WT1 rs16754 showed a relatively low prevalence of BCR-ABL1-negative MPN, compared with those carrying wild A alleles of WT1 rs16754 (Hazard ratio 0.10-0.65, P<0.05). Therefore, possession of the variant G allele of WT1 rs16754 may reduce the risk of developing BCR-ABL1-negative MPN.
Adult ; Aged ; Aged, 80 and over ; Alleles ; Asian Continental Ancestry Group/*genetics ; Case-Control Studies ; Exons ; Female ; Fusion Proteins, bcr-abl/genetics ; Gene Frequency ; Genotype ; Humans ; Leukemia, Myeloid, Acute/pathology ; Male ; Middle Aged ; Myeloproliferative Disorders/*genetics/pathology ; Polymorphism, Single Nucleotide ; Prognosis ; Proportional Hazards Models ; Republic of Korea ; Risk ; Sequence Analysis, DNA ; WT1 Proteins/*genetics ; Young Adult

BACKGROUND: Following induction chemotherapy for AML, a sensitive determination of minimal residual disease (MRD) in patients achieving complete remission (CR) should enable the detection of early relapse. This study was designed to verify if quantitative assessment of the Wilms' tumor (WT1) gene by real time polymerase chain reaction (RQ-PCR) can be used as a marker for MRD detection during the monitoring of AML. METHODS: WT1 gene expression was quantified by RQ-PCR in 31 patients with AML at diagnosis (27 patients) and during follow-up (29 patients) relative to ABL control gene. In four patients, the WT1 gene expression was analyzed in comparison to a second PCR marker, PML-RARA fusion transcript. Prognostic significance of WT1 gene expression was analyzed at diagnosis and at the primary CR evaluation. Longitudinal WT1 gene analysis was performed in 17 AML patients. RESULTS: At diagnosis, WT1 gene expression exceeded the control level in all of the patients. Higher levels of WT1 gene expression were not associated with shorter event free survival or overall survival at diagnosis. Higher levels of WT1 gene expression were associated with shorter event free survival after induction chemotherapy. Relapse was observed in eight of 17 patients analysed longitudinally, and an increase of WT1 gene expression preceded morphologic relapse in four patients with the fusion transcript negative. Concomitant monitoring of PML-RARA fusion transcript reveals the lack of a significant correlation withWT1 gene expression. CONCLUSIONS: Quantitation of WT1 gene expression could be used for MRD monitoring of AML and for the early detection of relapse, especially in patients lacking specific molecular markers.
Adaptor Proteins, Signal Transducing/analysis ; Adult ; Aged ; Aged, 80 and over ; Female ; Follow-Up Studies ; Gene Expression ; *Genes, Wilms Tumor ; Humans ; Leukemia, Myelomonocytic, Acute/*diagnosis/mortality/therapy ; Male ; Middle Aged ; Neoplasm, Residual ; Polymerase Chain Reaction ; Prognosis ; Survival Analysis ; WT1 Proteins/*analysis/genetics